2-amino-thiazole-4-carboxylic acid dimethylamide | 827588-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-amino-thiazole-4-carboxylic acid dimethylamide
• 英文别名: 2-amino-N,N-dimethyl-1,3-thiazole-4-carboxamide
• CAS: 827588-49-8
• 化学式: C₆H₉N₃OS
• mdl: MFCD17221842
• 分子量: 171.223
• InChiKey: MZOQQOSGXMKUGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  87.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-amino-thiazole-4-carboxylic acid dimethylamide 、 4-methyl-1-oxo-2,3,4,9-tetrahydro-1H-β-carboline-6-carboxylic acid 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N,N-dimethyl-2-[(4-methyl-1-oxo-2,3,4,9-tetrahydropyrido[3,4-b]indole-6-carbonyl)amino]-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  The discovery of carboline analogs as potent MAPKAP-K2 inhibitors

  摘要：

  The discovery of a series of potent, carboline-based MK2 inhibitors is described. These compounds inhibit MK2 with IC(50)s as low as 10 nM, as measured in a DELFIA assay. An X-ray crystal structure reveals that they bind in a region near the p-loop and the hinge region of MK2a. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.101
• 作为产物：
  描述：

  (4-dimethylcarbamoyl-thiazol-2-yl)-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到2-amino-thiazole-4-carboxylic acid dimethylamide
  参考文献：
  名称：

  Substituted hydantoins

  摘要：

  本发明涉及以下公式的化合物，这些化合物在治疗以MEK高活性为特征的疾病方面具有用途。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病方面具有用途。

  公开号：

  US20060063814A1

文献信息

• Anti-Cytokine Heterocyclic Compounds
  申请人：Goldberg Daniel

  公开号：US20060276496A1

  公开（公告）日：2006-12-07

  Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

  杂环化合物及其类似物以及它们作为丝裂原活化蛋白激酶-2（MAPKAP-k2）抑制剂的用途，以及用于预防或治疗可以通过调节受试者中MAPKAP-K2活性来治疗或预防的疾病或紊乱的方法，以及包括这些MAPKAP-K2抑制剂的药物组合物和试剂盒。
• [EN] MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS DU RECEPTEUR GLUCOCORTICOIDE AP-1, ET/OU DE L'ACTIVITE DE NF- DOLLAR G(K)B, ET LEUR UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005072732A1

  公开（公告）日：2005-08-11

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-ĸB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1 - X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-ĸB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，其结构如公式（I）所示，其立体异构体，或其溶剂化物，或其前药，或其药用可接受盐，其中Z为CONR1R2或CH2NR1R2，其中至少一个X1-X8为N，R、Ra、Rb、Rc和Rd在此处定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病和炎症或免疫相关疾病的方法。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Duan Jingwu

  公开号：US20050182082A1

  公开（公告）日：2005-08-18

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR 1 R 2 or CH 2 NR 1 R 2 and where at least one of X 1 -X 8 is N, and R, R a , R b , R c and R d are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型的非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构式为（I）及其立体异构体、溶剂化物、前药或药物可接受的盐，其中Z为CONR1R2或CH2NR1R2，而X1-X8中至少有一个为N，R、Ra、Rb、Rc和Rd在此定义。还提供了药物组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法，包括上述化合物。
• MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF
  申请人：Bristol-Myers Squibb Company

  公开号：EP1708701A1

  公开（公告）日：2006-10-11
• EP1708701A4
  申请人：——

  公开号：EP1708701A4

  公开（公告）日：2009-06-17